Lisa M Cordes1, James L Gulley, Ravi A Madan. 1. aClinical Center, National Institutes of Health, Bethesda bGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: In recent clinical trials, immunotherapeutic agents have demonstrated promising results for the treatment of prostate cancer. This review discusses emerging immunotherapies for prostate cancer and their evolving role in sequencing and combination therapy. RECENT FINDINGS: Therapeutic vaccines including PROSTVAC and DCVAC/PCa have completed promising phase 2 trials for the treatment of prostate cancer and phase 3 trials are underway. Recent evidence supports a synergistic relationship between immunotherapy agents themselves, antiandrogens and with cytotoxic chemotherapy. Prostate cancer patients with good prognostic factors, such as minimal disease burden, appear to achieve the optimal benefit from immunotherapy. SUMMARY: Therapeutic cancer vaccines and immunomodulating agents have demonstrated activity in the treatment of prostate cancer. Immunotherapies may alter the prostate tumor microenvironment and ongoing studies aim to provide guidance on effective sequencing and combination strategies.
PURPOSE OF REVIEW: In recent clinical trials, immunotherapeutic agents have demonstrated promising results for the treatment of prostate cancer. This review discusses emerging immunotherapies for prostate cancer and their evolving role in sequencing and combination therapy. RECENT FINDINGS: Therapeutic vaccines including PROSTVAC and DCVAC/PCa have completed promising phase 2 trials for the treatment of prostate cancer and phase 3 trials are underway. Recent evidence supports a synergistic relationship between immunotherapy agents themselves, antiandrogens and with cytotoxic chemotherapy. Prostate cancerpatients with good prognostic factors, such as minimal disease burden, appear to achieve the optimal benefit from immunotherapy. SUMMARY: Therapeutic cancer vaccines and immunomodulating agents have demonstrated activity in the treatment of prostate cancer. Immunotherapies may alter the prostate tumor microenvironment and ongoing studies aim to provide guidance on effective sequencing and combination strategies.
Authors: Eric J Small; Raymond S Lance; Thomas A Gardner; Lawrence I Karsh; Lawrence Fong; Candice McCoy; Todd DeVries; Nadeem A Sheikh; Debraj GuhaThakurta; Nancy Chang; Charles H Redfern; Neal D Shore Journal: Clin Cancer Res Date: 2015-04-29 Impact factor: 12.531
Authors: M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon Journal: Proc Natl Acad Sci U S A Date: 2001-12-04 Impact factor: 11.205
Authors: Rebecca L Prue; Frank Vari; Kristen J Radford; Hui Tong; Melinda Y Hardy; Rachael D'Rozario; Nigel J Waterhouse; Tony Rossetti; Robert Coleman; Christopher Tracey; Hans Goossen; Vinay Gounder; Georgina Crosbie; Sonia Hancock; Stephanie Diaz-Guilas; Paul Mainwaring; Peter Swindle; Derek N J Hart Journal: J Immunother Date: 2015 Feb-Mar Impact factor: 4.456
Authors: Paul F Schellhammer; Gerald Chodak; James B Whitmore; Robert Sims; Mark W Frohlich; Philip W Kantoff Journal: Urology Date: 2013-04-09 Impact factor: 2.649
Authors: Yesim Eralp; Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; John M Polo; Lawrence B Lachman Journal: Breast Cancer Res Date: 2004-04-07 Impact factor: 6.466
Authors: Michael White; Andrew Freistaedter; Gwendolyn J B Jones; Emmanuel Zervos; Rachel L Roper Journal: PLoS One Date: 2018-02-23 Impact factor: 3.240